HOLX
Hologic, Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$76.01
+0.00%Year over year
Reported trailing growth
- Revenue
- +2.2%
- EBITDA
- -24.5%
- EBIT
- -23.8%
- EPS
- -23.6%
- Free cash flow
- -10.4%
- Operating cash flow
- -12.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -5.5%
- EBITDA
- -21.5%
- EBIT
- -24.2%
- Net income
- -24.3%
- EPS
- -21.6%
- Free cash flow
- -22.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025